Postmarketing Study Status Reports Need Sponsor Pre-Clearance - PhRMA
This article was originally published in The Tan Sheet
Executive Summary
Portions of postmarketing study annual status reports that will be publicly disclosed should be pre-specified by study sponsors, the Pharmaceutical Research & Manufacturers of America suggests to FDA in Feb. 14 comments.